Anti-inflammatory properties rather than anti-oxidant capability is the major mechanism of neuroprotection by sodium salicylate in a chronic rotenone model of Parkinson's disease

Neuroscience

Volumn 231, Issue , 2013, Pages 420-431

  Thakur, P ^a   Nehru, B ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Apoptosis; Neuroinflammation; Oxidative stress; Parkinson's disease; Rotenone; Sodium salicylate

Indexed keywords

CYCLOOXYGENASE 2; DOPAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; REACTIVE OXYGEN METABOLITE; SALICYLATE SODIUM; TUMOR NECROSIS FACTOR ALPHA; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DRUG MECHANISM; ENZYME INDUCTION; LIPID PEROXIDATION; MALE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN CARBONYLATION; RAT; WEIGHT CHANGE;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; BRAIN; CATALASE; CYTOKINES; DOPAMINE; HOMOVANILLIC ACID; INFLAMMATION; MALE; MONOAMINE OXIDASE; NEURONS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PARKINSON DISEASE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; ROTENONE; SODIUM SALICYLATE;

EID: 84872854169     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2012.11.006     Document Type: Article

References (58)

1. Amann R., Peskar B.A. Anti-inflammatory effects of aspirin and sodium salicylate. Eur J Pharmacol 2002, 447:1-9.
2. Anderson J.K. Oxidative stress in neurodegeneration, cause or consequence. Nat Rev Neurosci 2004, 5:S18-S25.
3. Aubin N., Curet O., Deffois A., Carter C. Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J. Neurochem 1998, 71:1635-1642.
4. Bayon Y., Alonso A., Sanchez Crespo M. 4-Trifluoromethyl derivatives of salicylate, triflusal and its main metabolite 2-hydroxy-4-trifluoromethylbenzoic acid, are potent inhibitors of nuclear factor kappaB activation. Br J Pharmacol 1999, 126:1359-1366.
5. Best T.M., Fiebig R., Corr D.T., Brickson S., Ji L. Free radical activity, antioxidant enzyme, and glutathione changes with muscle stretch injury in rabbits. J Appl Physiol 1999, 87(1):74-82.
6. Bishnoi M., Chopra K., Kulkarni S.K. Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes. Eur J Pharmacol 2006, 552:55-66.
7. Boyde T.R.C., Rahmatullah M. Optimization of conditions for the colorimetric determination of citrulline, using diacetyl monoxime. Anal Biochem J 1980, 107:424-431.
8. Bové J., Prou D., Perier C., Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2005, 2(3):484-494.
9. Brooks S.P., Trueman R.C., Dunnett S.B. Assessment of motor coordination and balance in mice using the rotarod, elevated bridge, and footprint tests. Curr Protoc Mouse Biol 2012, 2:37-53.
10. Burcham P.C. Modified protein carbonyl assay detects oxidised membrane proteins, a new tool for assessing drug- and chemically-induced oxidative cell injury. J Pharmacol Toxicol Methods 2007, 56(1):18-22.
11. Chen X., Tansey M.G. The role of neuroinflammation in Parkinson's disease. Neuroinflammation 2011, vol. 18:401-420. Elsevier, Oxford.
12. Costall B., Naylor R.J. On catalepsy and catatonia and the predictability of the catalepsy test for neuroleptic activity. Psychopharmacology 1974, 34:233-241.
13. Egashira T., Yamamoto T., Kuroiwa Y. Inhibition of monoamine oxidase by 3'-methyl-4-dimethylamino azobenzene (3'-me-DAB) in rat liver mitochondria. Jpn J Pharmacol 1982, 32(2):335-342.
14. Esposito E., Di Matteo V., Benigno A., Pierucci M., Crescimanno G., Di Giovanni G. Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp Neurol 2007, 205(2):295-312.
15. Ferger B., Teismann P., Earl C.D., Kuschinsky K., Oertel W.H. Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice. Naunyn-Schmiedebergs Arch Pharmacol 1999, 360:256-261.
16. Fisher J., Mizrahi T., Schori H., Yoles E., Levkovitch-Verbin H., Haggiag S., Revel M., Schwartz M. Increased post-traumatic survival of neurons in IL-6-knockout mice on a background of EAE susceptibility. J Neuroimmunol 2001, 119:1-9.
17. Floyd R.A. Antioxidants, oxidative stress and degenerative neurological disorders. Proc Soc Exp Biol Med 1999, 222(3):236-245.
18. Gao H.M., Liu B., Hong J.S. Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 2003, 23(15):6181-6187.
19. Giuliano F., Mitchell J.A., Warner T.D. Sodium salicylate inhibits prostaglandin formation without affecting the induction of cyclooxygenase-2 by bacterial lipopolysaccharide in vivo. J Pharmacol Exp Ther 2001, 299:894-900.
20. Giuliano F., Warner T.D. Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs. Br J Pharmacol 1999, 26:1824-1830.
21. Grilli M., Pizzi M., Memo M., Spano P. Neuroprotection by aspirin and sodium salicylate through blockade of NF-κB activation. Science 1996, 274:1383-1385.
22. Hald A., Lotharius J. Oxidative stress and inflammation in Parkinson's disease: is there a causal link?. Exp Neurol 2005, 193(2):279-290.
23. Hartlage-Rübsamen M., Lemke R., Schliebs R. Interleukin-1β, inducible nitric oxide synthase, and nuclear factor-κB are induced in morphologically distinct microglia after rat hippocampal lipopolysaccharide/interferon-γ injection. J Neurosci Res 1999, 57(3):388-398.
24. Hastings T.G. Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem 1995, 64:919-924.
25. Kanazawa A., Kondo T. Hydroxyl radicals generation and post ischemic reperfusion brain damage implications for neuroprotection. No to Shinkei. Brain Nerve 1996, 48:567-572.
26. Kim W.G., Mohney R.P., Wilson B., Jeohn G.H., Liu B., Hong J.S. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain, role of microglia. J Neurosci 2000, 20:6309-6316.
27. Kleinert H., Schwarz P.M., Förstermann U. Regulation of the expression of inducible nitric oxide synthase. Biol Chem 2003, 384(10-11):1343-1364.
28. Kono Y. Generation of superoxide radical during auto-oxidation of hydroxylamine and an assay of superoxide dismutase. Arch Biochem Biophys 1978, 186:189-195.
29. Kulkarni S.K. Handbook of experimental pharmacology 1999, Vallabh Prakashan, Delhi. 3rd ed.
30. Ladenheim B., Krasnova I.N., Deng X., Oyler J.M., Polettini A., Moran T.H., Huestis M.A., Cadet J.L. Methamphetamine-induced neurotoxicity is attenuated in transgenic mice with a null mutation for interleukin-6. Mol Pharmacol 2000, 58:1247-1256.
31. Lee J.K., Tran T., Tansey M.G. Neuroinflammation in Parkinson's disease. J Neuroimmune Pharmacol 2009, 4:419-429.
32. Litteljohn D., Mangano E., Clarke M., Bobyn J., Moloney K., Hayley S. Inflammatory mechanisms of neurodegeneration in toxin-based models of Parkinson's disease. Parkinsons Dis. 2010, 2011:713517.
33. Luck H. Methods in enzymatic analysis 1971, 885-893. Academic Press, New York. H.O. Bergmeyer (Ed.).
34. Ludolph A.C., He F., Spencer P.S., Hammerstad J., Sabri M. 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Can J Neurol Sci 1991, 18(4):492-498.
35. Ma X.C., Gottschall P.E., Chen L.T., Wiranowska M., Phelps C.P. Role and mechanisms of interleukin-1 in the modulation of neurotoxicity. Neuroimmunomodulation 2002, 10:199-207.
36. Malkus K.A., Tsika E., Ischiropoulos H. Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease, how neurons are lost in the Bermuda triangle. Mol Neurodegener 2009, 4:24.
37. Meredith G.E., Kang U.J. Behavioral models of Parkinson's disease in rodents: a new look at an old problem. Mov Disord 2006, 21(10):1595-1606.
38. Mitchell J.A., Akarasereenont P., Thiemermann C., Flower R.J., Vane J.R. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A 1994, 90:11693-11697.
39. Mohanakumar K.P., Muralikrishnan D., Thomas B. Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. Brain Res 2000, 864(2):281-290.
40. Moore A.H., Bigbee M.J., Boynton G.E., Wakeham C.M., Rosenheim H.M., Staral C.J., Morrissey J.L., Hund A.K. Non-Steroidal Anti-Inflammatory Drugs in Alzheimer's disease and Parkinson's disease, reconsidering the role of neuroinflammation. Pharmaceuticals 2010, 3(6):1812-1841.
41. Moore D.J., West A.B., Dawson V.L., Ted M., Dawson T.M. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 2005, 28:57-87.
42. Nehru B., Verma R., Khanna P., Sharma S.K. Behavioral alterations in rotenone model of Parkinson's disease: attenuation by co-treatment of centrophenoxine. Brain Res 2008, 12011:122-127.
43. Patrignani P., Panara M.R., Sciulli M.G., Santini G., Renda G., Patrono C. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Physiol Pharmacol 1997, 48:623-631.
44. Pott-Godoy M.C., Ferrari C.C., Pitossi F.J. Nigral neurodegeneration triggered by striatal AdIL-1 administration can be exacerbated by systemic IL-1 expression. J Neuroimmunol 2010, 222(1-2):29-39.
45. Qian L., Flood P.M., Hong J.S. Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy. J Neural Transm 2010, 117:971-979.
46. Raddassi K., Berthon B., Petit J.F., Lemaire G. Role of calcium in the activation of mouse peritoneal macrophages: induction of NO synthase by calcium ionophores and thapsigargin. Cell Immunol 1994, 53:443-455.
47. Rogers J., Kovelowski C.J. Inflammatory mechanism in Parkinson's disease. Neuroinflammation: mechanisms and management 2003, 391-403. Humana Press, Totowa, NJ. 2nd ed. P.L. Wood (Ed.).
48. Sairam K., Saravanan K.S., Banerjee R., Mohanakumar K.P. Nonsteroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Res 2003, 966:245-252.
49. Sanberg P.R., Bunsey M.D., Giordano M., Norman A.B. The catalepsy test: its ups and downs. Behav Neurosci 1988, 102(5):748-759.
50. Sherer T.B., Betarbet R., Kim J.H., Greenamyre J.T. Selective microglial activation in the rat rotenone model of Parkinson's disease. Neurosci Lett 2003, 341:87-90.
51. Shimpo M., Ikeda U., Maeda Y., Ohya K., Murakami Y., Shimada K. Effects of aspirin-like drugs on nitric oxide synthesis in rat vascular smooth muscle cells. Hypertension 2000, 35(5):1085-1091.
52. Sossi V., de la Fuente-Fernandez R., Holden J.E., Schulzer M., Ruth T.J., Stoessl J. Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms. J Cereb Blood Flow Metab 2004, 24:869-876.
53. Tegeder I., Pfeilschifter J., Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001, 15:2057-2072.
54. Wichmann T., Delong M.R. Neurocircuitry of Parkinson's disease. Neuropsychopharmacology: the fifth generation of progress 2002, 1761-1779. American College of Neuropsychopharmacology. K.L. Davis, D. Charney, J.T. Coyle, C. Nemeroff (Eds.).
55. Wills E.D. Mechanism of lipid peroxide formation in animal tissue. Biochem J 1966, 99:667-676.
56. Witte M.E., Geurts J.J., de Vries H.E., van der Valk P., van Horssen J. Mitochondrial dysfunction, a potential link between neuroinflammation and neurodegeneration?. Mitochondrion 2010, 10(5):411-418.
57. Xiong N., Xiong J., Khare G., Chen C., Huang J., Zhao Y., Zhang Z., Qiao X., Feng Y., Reesaul H., Zhang Y., Sun S., Lin Z., Wang T. Edaravone guards dopamine neurons in a rotenone model for Parkinson's disease. PLoS One 2011, 6(6):e20677.
58. Yacoubian T.A., Standaert D.G. Targets for neuroprotection in Parkinson's disease. Biochim Biophys Acta 2009, 1792:676-687.